In the PATH Study, patients stabilized on IVIg
Reported a 3.6-fold lower rate of systemic adverse reactions per infusion when switched to Hizentra†
93% of 4,225 total Hizentra infusions were free of any ARs.5
ARs occurring in ≥5% of subjects treated with Hizentra and at a higher frequency than placebo-treated subjects
|
Placebo n=57 |
0.2 g/kg Hizentra n=57 |
0.4 g/kg Hizentra n=58 |
Local Reactions‡ |
7.0% |
19.3% |
29.3% |
Headache |
3.5% |
7.0% |
6.9% |
Nasopharyngitis |
1.8% |
7.0% |
3.4% |
Fatigue |
1.8% |
8.8% |
0.0% |
Upper Respiratory Tract Infection |
3.5% |
5.3% |
3.4% |
Fall |
0.0% |
5.3% |
1.7% |
Back Pain |
1.8% |
5.3% |
1.7% |
Arthralgia |
1.8% |
5.3% |
1.7% |
Pain in Extremity |
0.0% |
1.8% |
5.2% |
Zero cases of thrombosis or hemolysis were observed in Hizentra patients in the PATH Study.5 Thrombosis or hemolysis may occur with Ig products, including Hizentra. For patients at risk of thrombosis, administer Hizentra at the minimum dose and infusion rate possible. Please see the boxed warning and section 5 of the full prescribing information for more details.
In the PATH Study
More than 7 of 10 CIDP patients on Hizentra did not report local reactions
- Local reactions were the most commonly reported ARs
- Reports of infusion-site reactions decreased in frequency over time
- No subject withdrew because of local reactions§